Thu, September 22, 2022

Robyn Karnauskas Maintained (BIIB) at Strong Buy with Decreased Target to $265 on, Sep 22nd, 2022

Robyn Karnauskas of Truist Securities, Maintained "Biogen Inc." (BIIB) at Strong Buy with Decreased Target from $270 to $265 on, Sep 22nd, 2022.

Robyn has made no other calls on BIIB in the last 4 months.



There are 5 other peers that have a rating on BIIB. Out of the 5 peers that are also analyzing BIIB, 2 agree with Robyn's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Maintained at Hold with Decreased Target to $223 on, Monday, September 12th, 2022
  • Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $200 on, Thursday, July 21st, 2022


These are the ratings of the 3 analyists that currently disagree with Robyn


  • Phil Nadeau of "Cowen & Co." Maintained at Buy with Decreased Target to $270 on, Thursday, July 21st, 2022
  • Ami Fadia of "Needham" Maintained at Strong Buy with Decreased Target to $250 on, Thursday, July 21st, 2022
  • Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $230 on, Monday, July 18th, 2022